Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Retained Earnings (2016 - 2025)

Neurocrine Biosciences' Retained Earnings history spans 16 years, with the latest figure at $13.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 125.86% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $13.1 million, up 125.86%, while the annual FY2025 figure was $13.1 million, 125.86% up from the prior year.
  • Retained Earnings reached $13.1 million in Q4 2025 per NBIX's latest filing, down from $294.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $294.0 million in Q3 2025 to a low of -$693.3 million in Q1 2021.
  • Average Retained Earnings over 5 years is -$204.2 million, with a median of -$8.4 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 35422.22% in 2021, then soared 4870.59% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$635.8 million in 2021, then surged by 36.02% to -$406.8 million in 2022, then surged by 101.72% to $7.0 million in 2023, then fell by 17.14% to $5.8 million in 2024, then skyrocketed by 125.86% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Retained Earnings are $13.1 million (Q4 2025), $294.0 million (Q3 2025), and $84.5 million (Q2 2025).